---
title: "Zai Lab Expands Employee Equity Awards Under 2024 Incentive Plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281557795.md"
description: "Zai Lab Ltd has announced the granting of new equity awards under its 2024 Equity Incentive Plan, including share options and restricted share units to 45 option grantees and 471 RSU grantees. The plan includes 268,500 options priced at US$20.34 per ADS and 603,851 RSUs at no purchase price. These awards aim to retain and motivate employees, aligning their interests with long-term shareholder value. The current analyst rating for Zai Lab's stock (HK:9688) is a Hold with a price target of HK$15.00."
datetime: "2026-04-02T15:47:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281557795.md)
  - [en](https://longbridge.com/en/news/281557795.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281557795.md)
---

# Zai Lab Expands Employee Equity Awards Under 2024 Incentive Plan

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An announcement from Zai Lab Ltd ( (HK:9688) ) is now available.

Zai Lab has granted a new round of share options, restricted share units, and performance share units to employees under its 2024 Equity Incentive Plan, covering 45 option grantees and 471 RSU grantees. The options, totaling 268,500 ADSs with a 10-year term and four-year vesting schedule, are priced at US$20.34 per ADS, while 603,851 RSUs are granted at no purchase price.

The compensation committee said the awards, which do not carry performance targets or clawback terms, are designed to retain and motivate staff and are consistent with market practice and the company’s established approach to equity incentives. The grants expand employee ownership and are intended to align staff interests with long-term shareholder value, potentially strengthening Zai Lab’s ability to compete for talent in the biopharmaceutical sector.

The most recent analyst rating on (HK:9688) stock is a Hold with a HK$15.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.

**More about Zai Lab Ltd**

Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands and listed in Hong Kong and on Nasdaq. The company focuses on discovering, developing, and commercializing innovative medicines, with a workforce that is incentivized through equity-based compensation aligned with global biotech industry practices.

**Average Trading Volume:** 9,861,692

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$17.15B

### Related Stocks

- [09688.HK](https://longbridge.com/en/quote/09688.HK.md)
- [ZLAB.US](https://longbridge.com/en/quote/ZLAB.US.md)

## Related News & Research

- [Zai Lab Grants New Share Options and RSUs Under 2024 Equity Plan](https://longbridge.com/en/news/286070641.md)
- [Zai Lab Q1 2026 Results Highlight Pipeline Momentum and Upcoming China Launches](https://longbridge.com/en/news/285564515.md)
- [08:28 ETDrugBank Launches Advisory Board to Guide AI Adoption in Biopharma](https://longbridge.com/en/news/286099221.md)
- [09:30 ETZifo Now Partners with 7 of the Top 15 Global Biopharma Companies to Unblock the CMC Process Data Pipeline](https://longbridge.com/en/news/285952644.md)
- [Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong Kong](https://longbridge.com/en/news/286072114.md)